Cited by 351Monoclonal and Polyclonal Antibodies ResearchToxin Mechanisms and ImmunotoxinsProtein purification and stability

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity.

Open access

Mack, M, Riethmüller, G, Kufer, P·1995·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.92.15.7021PMC PMC41463

Open this paper in CoChat — free account

Abstract

Construction of a bispecific single-chain antibody derivative is described that consists of two different single-chain Fv fragments joined through a Gly-Ser linker. One specificity of the two Fv fragments is directed against the CD3 antigen of human T cells and the other is directed against the epithelial 17-1A antigen; the latter had been found in a clinical trial to be a suitable target for antibody therapy of minimal residual colorectal cancer. The construct could be expressed in CHO cells as a fully functional protein, while its periplasmic expression in Escherichia coli resulted in a nonfunctional protein only. The antigen-binding properties of the bispecific single-chain antibody are indistinguishable from those of the corresponding univalent single-chain Fv fragments. By redirecting human peripheral T lymphocytes against 17-1A-positive tumor cells, the bispecific antibody proved to be highly cytotoxic at nanomolar concentrations as demonstrated by 51Cr release assay on various cell lines. The described bispecific construct has a molecular mass of 60 kDa and can be easily purified by its C-terminal histidine tail on a Ni-NTA chromatography column. As bispecific antibodies have already been shown to be effective in vivo in experimental tumor systems as well as in phase-one clinical trials, the small CD3/17-1A-bispecific antibody may be more efficacious than intact antibodies against minimal residual cancer cells.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1073/pnas.92.15.7021

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A new method for predicting signal sequence cleavage sites
von HEIJNE, G. (1986) · Nucleic Acids Research · doi:10.1093/nar/14.11.4683 · Cited by 4,473
Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA
Pelletier, J., & Sonenberg, N. (1988) · Nature · doi:10.1038/334320a0 · Cited by 1,953
Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.
Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M. S., Novotný, J., Margolies, M. N., Ridge, R. J., Bruccoleri, R. E., Haber, E., & Crea, R. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.16.5879 · Cited by 1,610
pEF-BOS, a powerful mammalian expression vector
Mizushima, S., & Nagata, S. (1990) · Nucleic Acids Research · doi:10.1093/nar/18.17.5322 · Cited by 1,594
Single-Chain Antigen-Binding Proteins
Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S., Lee, T. T., Pope, S. H., Riordan, G. S., & Whitlow, M. D. (1988) · Science · doi:10.1126/science.3140379 · Cited by 1,522
"Diabodies": small bivalent and bispecific antibody fragments.
Holliger, P., Prospero, T. D., & Winter, G. P. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6444 · Cited by 882
Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.
Yokota, T., Milenic, D. E., Whitlow, M. D., & Schlom, J. (1992) · PubMed · Cited by 819
Cloning immunoglobulin variable domains for expression by the polymerase chain reaction.
Orlandi, R., Güssow, D., Jones, P. T., & Winter, G. P. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.10.3833 · Cited by 715
Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma
Riethmüller, G., Gruber, R., Schneider-Gädicke, E., Schlimok, G., Witte, J., Raab, R., Pichlmayr, R., Pichlmaier, H., Schmiegel, W., Buggisch, P., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92398-1 · Cited by 633
Self-citation
Hybrid antibodies can target sites for attack by T cells
Staerz, U. D., Kanagawa, O., & Bevan, M. J. (1985) · Nature · doi:10.1038/314628a0 · Cited by 492

Show all 39 references

Research works printed but not linked: 6

[9]Staerz, U. D. & Bevan, M. J. (1986) Proc. Natl. Acad. Sci. USA 83, 1453–1457.
[13]Hollinger, P., Prospero, T. & Winter, G. (1993) Proc. Natl. Acad. Sci. USA 90, 6444–6448.
[16]Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M.-S., Novotny, J., Margolies, M. N., Ridge, R. J., Bruccoleri, R. E., Haber, E., Crea, R. & Oppermann, H. (1988) Proc. Natl. Acad. Sci. USA 85, 5879–5883.
[18]Orlandi, R., Güssow, D. H., Jones, P. T. & Winter, G. (1989) Proc. Natl. Acad. Sci. USA 86, 3833–3837.
[25]Szala, S., Froehlich, M., Scollon, M., Kasai, Y., Steplewski, Z., Koprowsky, H. & Linnebach, A. J. (1990) Proc. Natl. Acad. Sci. USA 87, 3542–3564.
[30]Brinkmann, U., Reiter, Y., Jung, S., Lee, B. & Pastan, I. (1993) Proc. Natl. Acad. Sci. USA 90, 7538–7542.

Sorted by citations

Items 101–200 of 351

Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
Kegyes, D., Constantinescu, C. S., Vrancken, L., Rasche, L., Grégoire, C., Țigu, A. B., Gulei, D., Dima, D. M., Tănase, A., Einsele, H., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01296-2 · Cited by 65
Epithelial tight junction proteins as potential antibody targets for pancarcinoma therapy
Offner, S., Hekele, A., Teichmann, U., Weinberger, S., Groß, S., Kufer, P., Itin, C., Baeuerle, P. A., & Kohleisen, B. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0613-x · Cited by 63
Self-citation
CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications
Steinmetz, A. C. U., Vallée, F., Beil, C., Lange, C. M., Baurin, N., Beninga, J., Capdevila, C., Corvey, C., Dupuy, A., Ferrari, P., et al. (2016) · mAbs · doi:10.1080/19420862.2016.1162932 · Cited by 59
T Cell-Redirecting Strategies to ‘STAb’ Tumors: Beyond CARs and Bispecific Antibodies
Blanco, B., Compte, M., Lykkemark, S., Sanz, L., & Álvarez‐Vallina, L. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.01.008 · Cited by 59
Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap
Longhitano, A., Slavin, M. A., Harrison, S. J., & Teh, B. W. (2021) · Blood Reviews · doi:10.1016/j.blre.2021.100810 · Cited by 60
Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis
Rongvaux, A., Shea, R. J., Mulks, M. H., Gigot, D., Urbain, J., Léo, O., & Andris, F. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200211)32:11 · Cited by 551
Effect of Domain Order on the Activity of Bacterially Produced Bispecific Single-chain Fv Antibodies
Kipriyanov, S. M., Moldenhauer, G., Braunagel, M., Reusch, U., Cochlovius, B., Gall, F. L., Kouprianova, O. A., von der Lieth, C., & Little, M. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00526-6 · Cited by 57
Characterization of a Bispecific FLT3 X CD3 Antibody in an Improved, Recombinant Format for the Treatment of Leukemia
Durben, M., Schmiedel, D., Hofmann, M., Vogt, F., Nuebling, T., Pyż, E., Bühring, H., Rammensee, H., Salih, H. R., Große‐Hovest, L., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.2 · Cited by 56
A brief introduction of IgG-like bispecific antibody purification: Methods for removing product-related impurities
Li, Y. (2018) · Protein Expression and Purification · doi:10.1016/j.pep.2018.11.011 · Cited by 55
One-Step Enzymatic Modification of the Cell Surface Redirects Cellular Cytotoxicity and Parasite Tropism
Swee, L. K., Lourido, S., Bell, G. W., Ingram, J. R., & Ploegh, H. L. (2014) · ACS Chemical Biology · doi:10.1021/cb500462t · Cited by 55
A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma
Gedeon, P. C., Schaller, T. H., Chitneni, S. K., Choi, B. D., Kuan, C., Suryadevara, C. M., Snyder, D. J., Schmittling, R. J., Szafranski, S. E., Cui, X., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0126 · Cited by 58
Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3
Schlereth, B., Kleindienst, P., Fichtner, I., Lorenczewski, G., Brischwein, K., Lippold, S., da Silva, A., Locher, M., Kischel, R., Lutterbüse, R., et al. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0082-x · Cited by 55
Self-citation
Recognition of human colon cancer by T cells transduced with a chimeric receptor gene
Daly, T., Royal, R. E., Kershaw, M. H., Treisman, J. S., Wang, G., Li, W., Herlyn, D., Eshhar, Z., & Hwu, P. (2000) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700121 · Cited by 54
Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia
Poon, L. M., Bassett, R. L., Rondón, G., Hamdi, A., Qazilbash, M. H., Hosing, C. M., Jones, R. B., Shpall, E. J., Popat, U., Nieto, Y. L., et al. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.195 · Cited by 54
Lipoxygenase-derived Metabolites Are Regulators of Peroxisome Proliferator-activated Receptor -2 Expression in Human Vascular Smooth Muscle Cells
Limor, R., Sharon, O., Knoll, E., Many, A., Weisinger, G., & Stern, N. (2008) · American Journal of Hypertension · doi:10.1038/ajh.2007.39 · Cited by 53
Novel immunotherapies for hematologic malignancies
Nelson, M. H., & Paulos, C. M. (2014) · Immunological Reviews · doi:10.1111/imr.12245 · Cited by 52
Targeting B-cell non Hodgkin lymphoma: New and old tricks
Solimando, A. G., Ribatti, D., Vacca, A., & Einsele, H. (2016) · Leukemia Research · doi:10.1016/j.leukres.2015.11.001 · Cited by 52
Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer
Kufer, P., Mack, M., Gruber, R., Lutterbüse, R., Zettl, F., & Riethmüller, G. (1997) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050431 · Cited by 51
Self-citation
A recombinant bispecific single‐chain Fv antibody against HLA class II and FcγRIII (CD16) triggers effective lysis of lymphoma cells
Bruenke, J., Fischer, B. E., Barbin, K., Schreiter, K., Wachter, Y., Mahr, K., Titgemeyer, F., Niederweis, M., Peipp, M., Zunino, S. J., et al. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04893.x · Cited by 51
Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma
Smits, N. C., & Sentman, C. L. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.9970 · Cited by 49
Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE®) antibody construct blinatumomab as a potential therapy
Zimmerman, Z. F., Maniar, T. N., & Nagorsen, D. (2014) · International Immunology · doi:10.1093/intimm/dxu089 · Cited by 48
Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
You, G., Won, J., Lee, Y., Moon, D., Park, Y., Lee, S. H., & Lee, S. (2021) · Vaccines · doi:10.3390/vaccines9070724 · Cited by 52
Inhibition of stromal matrix metalloproteases: Effects on breast-tumor promotion by fibroblasts
Noël, A., Hajitou, A., L'Hoir, C., Maquoi, E., Baramova, E. N., Lewalle, J.-M., Remacle, A. G., Kebers, F., Brown, P. D. N., Calberg‐Bacq, C. M., et al. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980413)76:2 · Cited by 94
Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer
Simão, D. C., Zarrabi, K. K., Mendes, J. L., da Luz, R., Garcia, J. A., Kelly, W. K., & Barata, P. C. (2023) · Cancers · doi:10.3390/cancers15051412 · Cited by 47
Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody
Moon, D., Tae, N., Park, Y., Lee, S., & Kim, D. H. (2022) · Immune Network · doi:10.4110/in.2022.22.e4 · Cited by 48
The promise of bispecific antibodies: Clinical applications and challenges
Lim, S. M., Pyo, K., Soo, R. A., & Cho, B. C. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102240 · Cited by 45
Template DNA-Strand Co-Segregation and Asymmetric Cell Division in Skeletal Muscle Stem Cells
Shinin, V., Gayraud-Morel, B., & Tajbakhsh, S. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-060-7_19 · Cited by 43
Depletion of CCR5-Expressing Cells with Bispecific Antibodies and Chemokine Toxins: A New Strategy in the Treatment of Chronic Inflammatory Diseases and HIV
Brühl, H., Cihak, J., Stangassinger, M., Schlöndorff, D., & Mack, M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.4.2420 · Cited by 42
Self-citation
Clinical overview of anti-CD19 BiTE® and ex vivo data from anti-CD33 BiTE® as examples for retargeting T cells in hematologic malignancies
Zugmaier, G., Klinger, M., Schmidt, M., & Subklewe, M. S. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.02.033 · Cited by 43
Fucose Removal from Complex-Type Oligosaccharide Enhances the Antibody-Dependent Cellular Cytotoxicity of Single-Gene–Encoded Bispecific Antibody Comprising of Two Single-Chain Antibodies Linked to the Antibody Constant Region
Natsume, A., Wakitani, M., Yamane‐Ohnuki, N., Shoji-Hosaka, E., Niwa, R., Uchida, K., Satoh, M., & Shitara, K. (2006) · The Journal of Biochemistry · doi:10.1093/jb/mvj157 · Cited by 42
Di-diabody: a novel tetravalent bispecific antibody molecule by design
Lu, D., Jimenez, X., Zhang, H., Atkins, A., Brennan, L., Balderes, P. J., Böhlen, P., Witte, L., & Zhu, Z. (2003) · Journal of Immunological Methods · doi:10.1016/s0022-1759(03)00251-5 · Cited by 42
Blinatumomab for the treatment of acute lymphoblastic leukemia
Kaplan, J. B., Grischenko, M., & Giles, F. J. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0289-4 · Cited by 41
The intriguing options of multispecific antibody formats for treatment of cancer.
Weidle, U. H., Tiefenthaler, G., Weiss, E. H., Georges, G. J., & Brinkmann, U. (2013) · PubMed · Cited by 40
Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans
Amann, M., Friedrich, M., Lutterbuese, P., Vieser, E., Lorenczewski, G., Petersen, L., Brischwein, K., Kufer, P., Kischel, R., Baeuerle, P. A., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0529-y · Cited by 40
Self-citation
Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments
Lu, D., Jimenez, X., Zhang, H., Böhlen, P., Witte, L., & Zhu, Z. (2002) · Journal of Immunological Methods · doi:10.1016/s0022-1759(02)00148-5 · Cited by 39
An efficient route to the production of an IgG-like bispecific antibody
Zuo, Z., Jimenez, X., Witte, L., & Zhu, Z. (2000) · Protein Engineering Design and Selection · doi:10.1093/protein/13.5.361 · Cited by 39
Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?
del Bano, J., Chames, P., Baty, D., & Kerfélec, B. (2015) · Antibodies · doi:10.3390/antib5010001 · Cited by 39
Design and Applications of Bispecific Heterodimers: Molecular Imaging and beyond
Luo, H., Hong, H., Yang, S. P., & Cai, W. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500115x · Cited by 37
In Vivo Retargeting of T Cell Effector Function by Recombinant Bispecific Single Chain Fv (Anti-CD3 × Anti-Idiotype) Induces Long-Term Survival in the Murine BCL1 Lymphoma Model
Jonge, J. D., Heirman, C., Veerman, M. D., Meirvenne, S. V., Moser, M., Léo, O., & Thielemans, K. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.3.1454 · Cited by 38
Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single‐chain diabody
Fortmüller, K., Alt, K., Gierschner, D., Wolf, P., Baum, V., Freudenberg, N., Wetterauer, U., Elsässer‐Beile, U., & Bühler, P. (2010) · The Prostate · doi:10.1002/pros.21274 · Cited by 37
Investigation of the effect of salt additives in Protein L affinity chromatography for the purification of tandem single-chain variable fragment bispecific antibodies
Chen, S. W., Tan, D. H., Yang, Y., & Zhang, W. (2020) · mAbs · doi:10.1080/19420862.2020.1718440 · Cited by 39
Development of bispecific antibodies in China: overview and prospects
Zhang, J., Yi, J., & Zhou, P. (2020) · Antibody Therapeutics · doi:10.1093/abt/tbaa011 · Cited by 38
Construction of a bispecific single chain antibody for recruitment of cytotoxic T cells to the tumour stroma associated antigen fibroblast activation protein
Wüest, T., Moosmayer, D., & Pfizenmaier, K. (2001) · Journal of Biotechnology · doi:10.1016/s0168-1656(01)00355-8 · Cited by 37
RECRUIT-TandAbs ® : Harnessing the Immune System to Kill Cancer Cells
McAleese, F., & Eser, M. (2012) · Future Oncology · doi:10.2217/fon.12.54 · Cited by 36
Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition
Yeku, O., Rao, T. D., Laster, I., Kononenko, A. P., Purdon, T. J., Wang, P., Cui, Z., Liu, H., Brentjens, R. J., & Spriggs, D. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663379 · Cited by 37
Design and expression of a stable bispecific scFv dimer with affinity for both glycophorin and N9 neuraminidase
Atwell, J. L., Pearce, L. A., Lah, M., GRUEN, L. C., Kortt, A. A., & Hudson, P. J. (1996) · Molecular Immunology · doi:10.1016/s0161-5890(96)00097-1 · Cited by 36
Current Options and Future Directions in Immune Therapy for Glioblastoma
Lynes, J. P., Sánchez, V., Dominah, G. A., Nwankwo, A., & Nduom, E. K.-E. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00578 · Cited by 36
Monospecific bivalent scFv-SH: Effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility
Albrecht, H., DeNardo, G. L., & DeNardo, S. J. (2006) · Journal of Immunological Methods · doi:10.1016/j.jim.2005.12.012 · Cited by 35
Differentially Spliced Isoforms of FAT1 Are Asymmetrically Distributed within Migrating Cells
Braun, G. S., Kretzler, M., Heider, T., Floege, J., Holzman, L. B., Kriz, W., & Moeller, M. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701758200 · Cited by 33
A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis
Xie, Z., Guo, N., Yu, M., Hu, M., & Shen, B. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.11.005 · Cited by 33
Recent Advances on Immune Targeted Therapy of Colorectal Cancer Using bi-Specific Antibodies and Therapeutic Vaccines
Azadi, A., Golchini, A., Delazar, S., Kahaki, F. A., Dehnavi, S. M., Payandeh, Z., & Eyvazi, S. (2021) · Biological Procedures Online · doi:10.1186/s12575-021-00147-7 · Cited by 32
For whom the T cells troll? Bispecific T-cell engagers in glioblastoma
Singh, K., Hotchkiss, K. M., Mohan, A. A., Reedy, J. L., Sampson, J. H., & Khasraw, M. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003679 · Cited by 35
Accessing Diverse Pyridine-Based Macrocyclic Peptides by a Two-Site Recognition Pathway
Nguyen, D. T., Le, T., Rice, A. J., Hudson, G. A., van der Donk, W. A., & Mitchell, D. A. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c02824 · Cited by 31
Functional comparison of single-chain and two-chain anti-CD3-based bispecific antibodies in gene immunotherapy applications
Compte, M., Álvarez‐Cienfuegos, A., Nuñez‐Prado, N., Sainz-Pastor, N., Blanco‐Toribio, A., Pescador, N., Sanz, L., & Álvarez‐Vallina, L. (2014) · OncoImmunology · doi:10.4161/onci.28810 · Cited by 31
Selective inhibition of IDO1, D-1-methyl-tryptophan (D-1MT), effectively increased EpCAM/CD3-bispecific BiTE antibody MT110 efficacy against IDO1hibreast cancer via enhancing immune cells activity
Hong, R., Zhou, Y., Tian, X., Wang, L., & Wu, X. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.10.008 · Cited by 31
A tumor vaccine containing anti‐CD3 and anti‐CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes
Haas, C., Lulei, M., Fournier, P., Arnold, A., & Schirrmacher, V. (2005) · International Journal of Cancer · doi:10.1002/ijc.21390 · Cited by 31
Minimal costimulatory requirements for T cell priming and TH1 differentiation: activation of naive human T lymphocytes by tumor cells armed with bifunctional antibody constructs.
Kufer, P., Zettl, F., Borschert, K., Lutterbüse, R., Kischel, R., & Riethmüller, G. (2001) · PubMed · Cited by 31
Self-citation
[Pharmacokinetics and metabolism of trazodone in man (author's transl)].
Jauch, R., Kopitar, Z., Prox, A., & Zimmer, A. (1976) · PubMed · Cited by 31
Cancer Immunotherapy by Retargeting of Immune Effector Cells via Recombinant Bispecific Antibody Constructs
Stamova, S., Koristka, S., Keil, J., Arndt, C., Feldmann, A., Michalk, I., Bartsch, H., Bippes, C. C., Schmitz, M., Cartellieri, M., et al. (2012) · Antibodies · doi:10.3390/antib1020172 · Cited by 30
Anti- CD16/CD30 Bispecific Antibodies as Possible Treatment for Refractory Hodgkin's Disease
Hartmann, F., Renner, C., Jung, W. E., & Pfreundschuh, M. (1998) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199809059232 · Cited by 30
Efficient tumor cell lysis by autologous, tumor‐resident T lymphocytes in primary ovarian cancer samples by an EP‐CAM‐/CD3‐bispecific antibody
Wimberger, P., Xiang, W., Mayr, D. C., Diebold, J., Dreier, T., Baeuerle, P. A., & Kimmig, R. (2003) · International Journal of Cancer · doi:10.1002/ijc.11056 · Cited by 30
The CEA/CD3-Bispecific Antibody MEDI-565 (MT111) Binds a Nonlinear Epitope in the Full-Length but Not a Short Splice Variant of CEA
Peng, L., Oberst, M. D., Huang, J., Brohawn, P. Z., Morehouse, C., Lekstrom, K. J., Baeuerle, P. A., Wu, H., Yao, Y., Coats, S. R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036412 · Cited by 29
The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is now
Salcedo, L. M. J., Sandoval-Sus, J. D., Sokol, L., Chávez, J. C., & Dalia, S. M. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.027 · Cited by 30
Anti‐digoxin scFv fragments expressed in bacteria and in insect cells have different antigen binding properties
Lemeulle, C., Chardès, T., Montavon, C., Chaabihi, H., Mani, J. C., Pugnière, M., Cérutti, M., Devauchelle, G., Pau, B., & Biard‐Piechaczyk, M. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00029-5 · Cited by 28
T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine
Haas, C., Lulei, M., Fournier, P., Arnold, A., & Schirrmacher, V. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.10.031 · Cited by 28
A Novel Bispecific Antibody, S-Fab, Induces Potent Cancer Cell Killing
Li, L., He, P., Zhou, C., Jing, L., Dong, B., Chen, S., Zhang, N., Liu, Y., Miao, J. H., Wang, Z., et al. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000099 · Cited by 27
Alternative Antibody Formats
Gall, F. L., & Little, M. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511596773.018 · Cited by 27
Immunotherapies against HER2-Positive Breast Cancer
Duro‐Sánchez, S., Alonso, M. R., & Arribas, J. (2023) · Cancers · doi:10.3390/cancers15041069 · Cited by 29
Investigational Immunotherapeutics for B-Cell Malignancies
Quintás‐Cardama, A., Wierda, W. G., & O'Brien, S. M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8254 · Cited by 27
Bispecific antibodies for treatment of cancer in experimental animal models and man
Kroesen, B. J., Helfrich, W., Molema, G., & de Leij, L. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00096-3 · Cited by 27
Preclinical and clinical data with bispecific antibodies recruiting myeloid effector cells for tumor therapy
vanOjik, H. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00135-9 · Cited by 26
T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants
Messaoudene, M., Mourikis, T. P., Michels, J., Fu, Y., Bonvalet, M., Lacroix‐Triki, M., Routy, B., Fluckiger, A., Rusakiewicz, S., Roberti, M. P., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz112 · Cited by 26
T-cell activation and cytokine production via a bispecific single-chain antibody fragment targeted to blood-stage malaria parasites
Yoshida, S., Kobayashi, T., Matsuoka, H., Seki, C., Gosnell, W. L., Chang, S. P., & Ishii, A. (2003) · Blood · doi:10.1182/blood-2002-03-0831 · Cited by 26
An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma
Gedeon, P. C., Choi, B. D., Hodges, T. R., Mitchell, D. A., Bigner, D. D., & Sampson, J. H. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2013.811806 · Cited by 26
GPI-anchored TIMP-1 treatment renders renal cell carcinoma sensitive to FAS-meditated killing
Djafarzadeh, R., Nößner, E., Engelmann, H., Schendel, D. J., Notohamiprodjo, M., von Luettichau, I., & Nelson, P. J. (2005) · Oncogene · doi:10.1038/sj.onc.1209188 · Cited by 25
A new model for intermediate molecular weight recombinant bispecific and trispecific antibodies by efficient heterodimerization of single chain variable domains through fusion to a Fab-chain
Schoonjans, R., Willems, A. V., Schoonooghe, S., Leœn, J., Grooten, J., & Mertens, N. (2001) · Biomolecular Engineering · doi:10.1016/s1389-0344(01)00066-1 · Cited by 25
Targeting Dual Immune Checkpoints PD‐L1 and HLA‐G by Trispecific T Cell Engager for Treating Heterogeneous Lung Cancer
Lin, Y., Chen, M., Huang, S., Chen, Y., Ho, J. H., Lin, F., Tan, X., Chiang, H., Huang, C., Tu, C., et al. (2024) · Advanced Science · doi:10.1002/advs.202309697 · Cited by 24
Management of relapsed acute lymphoblastic leukemia in childhood with conventional and innovative approaches
Locatelli, F., Moretta, F., & Rutella, S. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000011 · Cited by 24
Engineering Immune Cells for in vivo Secretion of Tumor-Specific T Cell-Redirecting Bispecific Antibodies
Blanco, B., Ramírez-Fernández, Á., & Álvarez‐Vallina, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01792 · Cited by 25
Development and Characterization of a Bispecific Single-Chain Antibody Directed Against T Cells and Ovarian Carcinoma
Kriangkum, J., Xu, B., Gervais, C., Paquette, D., Jacobs, F. A., Martin, L., & Suresh, M. R. (2000) · Hybridoma · doi:10.1089/027245700315770 · Cited by 24
Committing Cytomegalovirus-Specific CD8 T Cells to Eliminate Tumor Cells by Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules
Schmittnaegel, M., Levitsky, V., Hoffmann, E., Georges, G. J., Mundigl, O., Klein, C., & Knoetgen, H. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0037 · Cited by 24
Therapeutic bispecific antibodies against intracellular tumor antigens
Xu, G., Luo, Y., Wang, H., Wang, Y., Liu, B., & Wei, J. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215699 · Cited by 23
Aptamers as potential therapeutic agents for ovarian cancer
Henri, J., MacDonald, J. P., Strom, M., Duan, W., & Shigdar, S. L. (2017) · Biochimie · doi:10.1016/j.biochi.2017.12.001 · Cited by 22
A bispecific immunotweezer prevents soluble PrP oligomers and abolishes prion toxicity
Bardelli, M., Frontzek, K., Simonelli, L., Hornemann, S., Pedotti, M., Mazzola, F., Carta, M. C., Eckhardt, V., D’Antuono, R., Virgilio, T., et al. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1007335 · Cited by 22
Mesothelin/CD3 Half-Life–Extended Bispecific T-Cell Engager Molecule Shows Specific Tumor Uptake and Distributes to Mesothelin and CD3-Expressing Tissues
Suurs, F. V., Lorenczewski, G., Bailis, J. M., Stienen, S., Friedrich, M., Lee, F., van der Vegt, B., de Vries, E. G. E., de Groot, D. J. A., & Hooge, M. N. L. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.259036 · Cited by 22
Potent, Selective CARs as Potential T-Cell Therapeutics for HPV-positive Cancers
Wang, X., Sandberg, M. L., Martin, A. D., Negri, K. R., Gabrelow, G. B., Nampe, D. P., Wu, M.-L., McElvain, M. E., Warshaviak, D. T., Lee, W.-H., et al. (2021) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000386 · Cited by 22
The Biodistribution of a CD3 and EpCAM Bispecific T-Cell Engager Is Driven by the CD3 Arm
Suurs, F. V., Lorenczewski, G., Stienen, S., Friedrich, M., de Vries, E. G. E., de Groot, D. J. A., & Hooge, M. N. L. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.241877 · Cited by 22
Generation and characterization of a novel tetravalent bispecific antibody that binds to hepatitis B virus surface antigens
Park, S. S., Ryu, C. J., Kang, Y. J., Kashmiri, S. V. S., & Hong, H. J. (2000) · Molecular Immunology · doi:10.1016/s0161-5890(01)00027-x · Cited by 22
Clinical perspectives of bispecific antibodies in cancer
GAST, G. C. D., van de Winkel, J. G. J., & Bast, B. J. E. G. (1997) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050412 · Cited by 22
Costimulation by CD28 sFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigen
Hayden, M. S., Grosmaire, L. S., Norris, N. A., Gillil, L. K., Winberg, G., Tritschler, D., Tsu, T. T., Lihsley, P. S., Mittler, R. S., Senter, P. D., et al. (1996) · Tissue Antigens · doi:10.1111/j.1399-0039.1996.tb02642.x · Cited by 21
Characterization of Bispecific T-cell Engager (BiTE®) Antibodies with a High-Capacity T-cell Dependent Cellular Cytotoxicity (TDCC) Assay
Nazarian, A. A., Archibeque, I., Nguyen, Y., Wang, P., Sinclair, A. M., & Powers, D. A. (2014) · SLAS DISCOVERY · doi:10.1177/1087057114561405 · Cited by 21
Production and characterization of an anti-(MUC1 mucin) recombinant diabody
Denton, G., Brady, K., Lo, B. K. C., Murray, A., Rosamund, C., Graves, L., Hughes, O. D. M., Tendler, S. J. B., Laughton, C. A., & Price, M. R. (1999) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050545 · Cited by 21
Antitumor Immunity: Easy as 1, 2, 3 with Monoclonal Bispecific Trifunctional Antibodies?
Maher, J. F., & Adami, A. A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1852 · Cited by 20
Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor
Fu, M., He, Q., Guo, Z., Zhou, X., Li, H., Zhao, L., Tang, H., Zhou, X., Zhu, H., Shen, G., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01396 · Cited by 20
Detection of a phosphorylated glycine-serine linker in an IgG-based fusion protein
Tyshchuk, O., Völger, H. R., Ferrara, C., Bulau, P., Koll, H., & Mølhøj, M. (2016) · mAbs · doi:10.1080/19420862.2016.1236165 · Cited by 20
Bispecific single-chain antibodies as effective tools for eliminating epithelial cancer cells from human stem cell preparations by redirected cell cytotoxicity
Maletz, K., Kufer, P., Mack, M., Raum, T., Pantel, K., Riethm�ller, G., & Gruber, R. (2001) · International Journal of Cancer · doi:10.1002/ijc.1348 · Cited by 19
Self-citation
A strategy to identify linker-based modules for the allosteric regulation of antibody-antigen binding affinities of different scFvs
Kellmann, S.-J., Dübel, S., & Thie, H. (2017) · mAbs · doi:10.1080/19420862.2016.1277302 · Cited by 19
AZ17: a new bispecific drug targeting IL-6 and IL-23 with potential clinical use—improves psoriasis in a human xenograft transplantation model
Stenderup, K., Rosada, C., Shanebeck, K. D., Brady, W., Brunt, M. P. V., King, G., Marelli, M., Slagle, P. H., Xu, H., Nairn, N. W., et al. (2015) · Protein Engineering Design and Selection · doi:10.1093/protein/gzv034 · Cited by 18
Soluble trivalent engagers redirect cytolytic T cell activity toward tumor endothelial marker 1
Fierle, J. K., Brioschi, M., de Tiani, M., Wetterwald, L., Atsaves, V., Abram-Saliba, J., Petrova, T. V., Coukos, G., & Dunn, S. M. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100362 · Cited by 18
Cardiotoxicities of Novel Therapies in Hematologic Malignancies: Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Therapy
Marar, R. I., Abbasi, M. A., Prathivadhi-Bhayankaram, S. V., Daryanani, A. E., Villarraga, H. R., Anavekar, N. S., Bhatt, V. R., & Paludo, J. (2023) · JCO Oncology Practice · doi:10.1200/op.22.00713 · Cited by 19

Authors: Mack, M., Riethmüller, G., & Kufer, P.
Affiliations: Institut für Immunologie (DE)
ORCID: Mack, M
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 1995-07-18
Volume: 92
Issue: 15
Pages: 7021-7025
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.92.15.7021
PMC: PMC41463
OpenAlex: W2086146164
Cited by: 351
References: 39
Citations by year: 2026: 8 · 2025: 11 · 2024: 15 · 2023: 7 · 2022: 10 · 2021: 20 · 2020: 12 · 2019: 22 · 2018: 19 · 2017: 20 · 2016: 12 · 2015: 22 · 2014: 16 · 2013: 13 · 2012: 14
FWCI: 12.32
Type: journal article
Language: en
Open access: green
europepmc.org
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Life Sciences › Immunology and Microbiology › Immunology › Toxin Mechanisms and Immunotoxins
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
Keywords: bispecific antibodies, single-chain antibody, single-chain Fv fragments, CD3 antigen, colorectal cancer, minimal residual disease, tumor cell killing, CHO cell expression, Ni-NTA affinity purification, antibody therapy
MeSH terms: Amino Acid Sequence, Antibody Specificity, Antineoplastic Agents, Base Sequence, Cloning, Molecular, Escherichia coli, Immunoglobulin Fragments, Immunoglobulin Variable Region, Molecular Sequence Data, Recombinant Proteins, Tumor Cells, Cultured, Blotting, Western

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks